• by Bruce Carlson
  • September 12 2018


Testing for Tick-Borne Diseases is a Big Business

Testing for Tick-Borne Diseases is a Big Business

Strong demand in TBD testing fueled by new threats, new innovations, increase in disease awareness, and unsatisfied patients seeking answers.

  • by Bruce Carlson
  • September 11 2018
  • IVD


5 Fast Facts About the IVD Market

The world market for diagnostics is estimated at $65 billion in 2018 and is expected to grow 4% annually to $77.8 billion by 2023. This includes all laboratory and hospital-based products, and OTC product sales. Previous editions had growth at 5-6%. growth has lowered due to reimbursement limitations. Yet there is plenty of reason for optimism too.


Theranos Finally Bleeds Out

Theranos Finally Bleeds Out

Blood-testing company Theranos, once worth $9 billion, is dissolving, having hemorrhaged billions thanks to fraudulent claims—not to mention actual fraud committed—by founder and "industry disruptor" Elizabeth Holmes.


PAMA brings huge changes to lab price testing, faces resistance from ACLA

PAMA brings huge changes to lab price testing, faces resistance from ACLA

The Protecting Access to Medicare Act (PAMA) of 2014 has surprised the industry with sweeping, potentially devastating cuts to how lab tests are reimbursed through Medicare, with a whole host of tests seeing cuts of over a third. The American Clinical Laboratory Association (ACLA) is fighting back with a lawsuit over the methodology of the Centers for Medicare and Medicaid’s (CMS) data collection in determining the new pricing scheme. The American Association for Clinical Chemistry (AACC) also weighs in, and asserts that labs will need to make some big changes if they want to survive.

  • by Bruce Carlson
  • August 28 2018


$77.8 Billion-Dollar IVD Market by 2023: New Report

$77.8 Billion-Dollar IVD Market by 2023: New Report

Drivers outweigh limiters when it comes to the IVD market, according to Kalorama Information's latest IVD report, the 11th edition. Test procedures are up and will be up, but cost-cutting form major payors is limiting marketing growth slightly faster than emergings can make up for it. This article highlights some of the key findings of the report.


$32 Billion-Dollar Market for Vaccines

$32 Billion-Dollar Market for Vaccines

The market, driven by new products and increased usage in emerging markets, grows to 32 billion. But not without challenges.

  • by Bruce Carlson
  • July 27 2018
  • IVD


20+ Things We're Excited About Seeing at AACC 2018

20+ Things We're Excited About Seeing at AACC 2018

A preview of announced developments at the upcoming American Association for Clinical Chemistry meeting in Chicago, which starts July 29th.


Janssen mAb Product Performance Drives Growth in Company

Janssen mAb Product Performance Drives Growth in Company

J&J beat expectations last quarter, due to the strength of its cancer treatment segment and particularly the myeloma drug Darzalex. We were not surprised. We had predicted increased growth in this segment of mAbs in our report, What's Trending in Monoclonal Antibodies.


Capillary Sequencing Still Present While NGS System Use Grows

Capillary Sequencing Still Present While NGS System Use Grows

Our latest report in Next Generation Sequencing markets tracks the persistence of older systems.


The State of Next Generation Sequencing, in a Glimpse

The State of Next Generation Sequencing, in a Glimpse

A look into the state of things NGS-related with a brief selection of the industry's major players. Plus, an announcement regarding the AACC's 2018 meeting in Chicago.